New Drug Application for Technology Developed at UIC and Rush University
A new, non-hormonal, vaginal gel contraceptive initially developed by Dr. Donald P Waller of UIC and Drs. Lourens Zaneveld and Robert Anderson of Rush University Medical Center has cleared phase III clinical trials, and a New Drug Application (proposed trade name: Amphora) has been accepted for filing by the United States Food and Drug Administration (FDA). This technology was first licensed in 2003 to EvoFEM, a startup that discovers, develops and commercializes products in the areas of feminine health and hygiene.
Modified on August 14, 2017